@Ajjax did discern from a crystal ball that: Heading back to...

@Ajjax did discern from a crystal ball that: Heading back to $5.

Probably not that low, unless something attributable goes badly awry with the health of any patients in trials.

Volume very low, apart from a couple of brief flurries before and after NYE - which didn't move the needle much.

I think the jury's still out on holidays.

But anyone looking at this stock with fresh eyes is likely to conclude the downturn amid general disinterest will continue.
Which is why last week I sold off most of what I held.
Looking for re-entry in a little while...
P.